Medication for Treatment of OCD: Understanding the Options

Medication for Treatment of OCD: Understanding the Options

Michael Ziffra, MD

ziffra-adhd-anxiety-michael

Dr. Michael Ziffra is an Associate Professor in the Department of Psychiatry at the Northwestern University Feinberg School of Medicine. He has been a clinician-educator in the department since 2006. Dr. Ziffra’s clinical interests include anxiety disorders and mood disorders.  He is actively involved as a teacher and supervisor in Northwestern’s psychiatry residency program.  Dr. Ziffra also has had much interest in educating the general public on issues related to mental health.  He is a 2002 graduate of the Northwestern University Feinberg School of Medicine and a 2006 graduate of the Harvard Longwood Psychiatry Residency Training Program.

Boost Search Results
On

Medication for Treatment of OCD: Understanding the Options

Share
Yes
OCD and Medication Michael Ziffra

Obsessive-compulsive disorder (OCD) is a complex diagnosis, with many distinct manifestations and varied degrees of severity.  Though OCD symptoms can severely affect functioning and quality of life, many treatments have been shown to reduce suffering.

Evidence-based interventions for OCD include both medication and non-pharmacologic interventions.  For some patients, psychotherapeutic interventions such as cognitive-behavioral therapy (CBT) and exposure and response prevention (ERP) can adequately manage symptoms.  However for other patients, these interventions may prove insufficient, and in such cases, medication should be considered.

Although primary care physicians and other non-specialists in mental health feel comfortable managing less complicated anxiety-related disorders, OCD is a more complex diagnosis and ideally should be managed by a psychiatrist.  Before initiating medication, the psychiatrist will first do a thorough assessment to ensure that the diagnosis of OCD is accurate, and to determine the presence of coexisting conditions that may complicate the treatment.

The recommended initial pharmacologic treatment for OCD is an antidepressant from the class known as selective serotonin reuptake inhibitors (SSRIs).  This class includes some of the most well-known and commonly prescribed antidepressants, including:

  • Fluoxetine
  • Paroxetine
  • Sertraline
  • Fluvoxamine
  • Citalopram
  • Escitalopram

The medication is started at a low dose, and it is gradually increased, as needed and tolerated.  Evidence suggests that relatively high dosages of an antidepressant are needed to adequately manage OCD.  Therefore, it may take several months to reach a point where the antidepressant can provide a significant degree of clinical benefit.

Other types of antidepressants are sometimes considered.  This may be done when the SSRI does not provide sufficient benefit or causes side effects that are hard to tolerate.  Another class of antidepressants called serotonin-norepinephrine reuptake inhibitors (SNRIs) is sometimes considered.  SNRIs tend to be less likely to cause certain side effects that can occur with SSRIs (for example – sedation and weight gain).  However, the evidence base supporting the use of SNRIs for OCD is not as strong.

Another medication with which some patients may do well is an antidepressant called clomipramine, which is from an older class of antidepressants called tricyclic antidepressants.  (TCAs).  The effectiveness of clomipramine for OCD is comparable to that of SSRIs.  However the TCAs are more likely to cause adverse reactions called anticholinergic side effects (examples may include things such as dry mouth, constipation, and vision changes).  Therefore, clomipramine tends to be considered only when a patient has had unsuccessful trials of several other antidepressants.

In some situations, patients may receive partial benefit from an antidepressant, though they do not achieve full remission of the OCD with even a high dose of the medication.  In such cases, the psychiatrist may consider adding a second medication to the antidepressant.  This is an intervention often called augmentation.

Different types of medications can be used to augment an antidepressant.  For OCD, one category of medication commonly used for this purpose is a class called atypical antipsychotics.  This term is somewhat of a misnomer and can evoke many questions and concerns from patients.  This class of medication was initially approved to treat schizophrenia and similar illnesses in which patients experience symptoms that are psychotic in nature (such as hallucinations or delusions).

However, it has been found that atypical antipsychotics have many uses beyond treating schizophrenia.  They are commonly used to treat mood disorders such as bipolar disorder and major depressive disorder.  Research has also found that atypical antipsychotics are one of the most effective types of medication for augmenting an antidepressant for the treatment of OCD.

Within the family of atypical antipsychotics, several options are available, and they vary significantly in their therapeutic effect and side effect profile.  The specific side effect profile will often influence which particular agent a psychiatrist will choose.  For example, some atypical antipsychotics are sedating and can be helpful for patients who are experiencing insomnia at night.  Conversely, patients who are more concerned about potential sedation may do better with an antipsychotic that has more of a stimulating quality.  

If patients with OCD do not experience remission of symptoms even after trying several different medications, they and their psychiatrist will discuss next steps.  If the patient is already not doing psychotherapeutic interventions such as CBT and ERP, adding these on can be extremely helpful.  The psychiatrist should also review with the patient whether additional psychiatric or medical diagnoses could be impeding the treatment.

Although OCD can be a complex and challenging diagnosis, many evidence-based treatment options are available.  A comprehensive evaluation and consultation with a psychiatrist can help patients understand which treatments will be most appropriate for their particular circumstance.


This post is presented in collaboration with ADAA's OCD and Related Disorders SIG. Learn more about the SIG.

Michael Ziffra, MD

ziffra-adhd-anxiety-michael

Dr. Michael Ziffra is an Associate Professor in the Department of Psychiatry at the Northwestern University Feinberg School of Medicine. He has been a clinician-educator in the department since 2006. Dr. Ziffra’s clinical interests include anxiety disorders and mood disorders.  He is actively involved as a teacher and supervisor in Northwestern’s psychiatry residency program.  Dr. Ziffra also has had much interest in educating the general public on issues related to mental health.  He is a 2002 graduate of the Northwestern University Feinberg School of Medicine and a 2006 graduate of the Harvard Longwood Psychiatry Residency Training Program.

Use of Website Blog Commenting

ADAA Blog Content and Blog Comments Policy

ADAA provides this Website blogs for the benefit of its members and the public. The content, view and opinions published in Blogs written by our personnel or contributors – or from links or posts on the Website from other sources - belong solely to their respective authors and do not necessarily reflect the views of ADAA, its members, management or employees. Any comments or opinions expressed are those of their respective contributors only. Please remember that the open and real-time nature of the comments posted to these venues makes it is impossible for ADAA to confirm the validity of any content posted, and though we reserve the right to review and edit or delete any such comment, we do not guarantee that we will monitor or review it. As such, we are not responsible for any messages posted or the consequences of following any advice offered within such posts. If you find any posts in these posts/comments to be offensive, inaccurate or objectionable, please contact us via email at [email protected] and reference the relevant content. If we determine that removal of a post or posts is necessary, we will make reasonable efforts to do so in a timely manner.

ADAA expressly disclaims responsibility for and liabilities resulting from, any information or communications from and between users of ADAA’s blog post commenting features. Users acknowledge and agree that they may be individually liable for anything they communicate using ADAA’s blogs, including but not limited to defamatory, discriminatory, false or unauthorized information. Users are cautioned that they are responsible for complying with the requirements of applicable copyright and trademark laws and regulations. By submitting a response, comment or content, you agree that such submission is non-confidential for all purposes. Any submission to this Website will be deemed and remain the property of ADAA.

The ADAA blogs are forums for individuals to share their opinions, experiences and thoughts related to mental illness. ADAA wants to ensure the integrity of this service and therefore, use of this service is limited to participants who agree to adhere to the following guidelines:

1. Refrain from transmitting any message, information, data, or text that is unlawful, threatening, abusive, harassing, defamatory, vulgar, obscene, that may be invasive of another 's privacy, hateful, or bashing communications - especially those aimed at gender, race, color, sexual orientation, national origin, religious views or disability.

Please note that there is a review process whereby all comments posted to blog posts and webinars are reviewed by ADAA staff to determine appropriateness before comments are posted. ADAA reserves the right to remove or edit a post containing offensive material as defined by ADAA.

ADAA reserves the right to remove or edit posts that contain explicit, obscene, offensive, or vulgar language. Similarly, posts that contain any graphic files will be removed immediately upon notice.

2. Refrain from posting or transmitting any unsolicited, promotional materials, "junk mail," "spam," "chain mail," "pyramid schemes" or any other form of solicitation. ADAA reserves the right to delete these posts immediately upon notice.

3. ADAA invites and encourages a healthy exchange of opinions. If you disagree with a participant 's post or opinion and wish to challenge it, do so with respect. The real objective of the ADAA blog post commenting function is to promote discussion and understanding, not to convince others that your opinion is "right." Name calling, insults, and personal attacks are not appropriate and will not be tolerated. ADAA will remove these posts immediately upon notice.

4. ADAA promotes privacy and encourages participants to keep personal information such as address and telephone number from being posted. Similarly, do not ask for personal information from other participants. Any comments that ask for telephone, address, e-mail, surveys and research studies will not be approved for posting.

5. Participants should be aware that the opinions, beliefs and statements on blog posts do not necessarily represent the opinions and beliefs of ADAA. Participants also agree that ADAA is not to be held liable for any loss or injury caused, in whole or in part, by sponsorship of blog post commenting. Participants also agree that ADAA reserves the right to report any suspicions of harm to self or others as evidenced by participant posts.

RESOURCES AND NEWS
Evidence-based Tips & Strategies from our Member Experts
RELATED ARTICLES
Block reference